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New drug is now entering
preliminary trials in humans

Uposomal dsplatin analogue is less
toxic and more effective than dsplatin
Lab to Clinic

Abdul Khokhar is an
associate professor of
medicine in the
Department of Clinical
Investigation

- - ~R
~o_m_a_n~Perez-s~0~1e-r -,s -anassociate professor of
medicine in the
Department of Thoracic/
Head and Neck Medical
Oncology

Since it.s discovery in 1969, cisplatin has proved to setting, and we feel strongly that we can apply what we
be one of the most effective agents for cancers of the learned with L-NDDP to the development of new,
head and neck, bladder, ovaries, and testes, but it.s use innovative therapies for our patient.s."
is limited by severe nephro- and neurotoxic side effect.s. Moreover, tumors eventually develop resistance Physician's propooal sparks chemist's interest
to it, rendering it ineffective against tumors previously
The story of L-NDDP's development begins in
treated with cisplatin. For two decades chemist.shave 1984. By that time, Khokhar had already established
been trying to develop new cisplatin analogues that are himselfas an expert in cisplatin analogue synthesis. For
just as effective as but less toxic than cisplatin. Several 14 years, since his initial work at the University Colanalogues that had these qualities have been success- lege, London, he had synthesized numerous cisplatin
fully synthesized, showing good anti.tumor activity in analogues.
laboratory studies. Unfortunately, some of these ana"In 1984, my analogue work was progressing nicely.
logues had an additional quality that made prospect.s I had just completed a second generation of analogues
for clinical application bleak: the drugs' lipophilicity when Dr. (Gabriel) Lopez-Berestein (Department of
made them insoluble in water, thus precluding in vivo Clinical Investigation) approached me with the idea of
administration.
synthesizing analogues that have a natural affinity for
A new family oflipophilic analogues, however, may liposomes," Khokhar said. "The theory was that lipoeventually eliminate these problems. One such mem- philic analogues could be more easily entrapped into
ber of this family, L-NDDP, is a liposome-encapsu- liposomes and thus more effective. No one had ever
lated cisplatin analogue developed by Abdul Khokhar, done this before. We were the first ones in the world
Ph.D., Department of Clinical Investigation, and to do it."
Roman Perez-Soler, M.D ., Department ofThoracic/ ·
Khokhar had already developed a lipophilic anaHead and Neck Medical Oncology. In animal models, logue as early as 1982, although he hadn't intended it
L-ND DP [ cis-bis-neodecanoato-trans-R,R-1,2-diam- for use with liposomes. The analogue was effective and
minocyclohexane platinum(II)] was less toxic and less toxic than cisplatin in laboratory studies, but it.s
more effective than cisplatin, and it showed only mini- lipophilicity made it insoluble in water. It, like other
mal cross-resistance with cisplatin. Lack of cross-resis- drugs of it.s kind, had found no clinical application.
tanceisakeyfeature,foritmeansthatcisplatin-resistant The possibility ofliposome delivery, however,
- tumGrs-ma~nefit-h)Ladditignal-tteatment-With L=--~formed-thi&a11alogue28Jiability-.intnanaturall)Lexploi NDDP. A phase I study using intravenous administra- able opportunity. The incident confirmed Khokhar's
tion in humans has just been completed, and two belief that successful drug development depends on
phase I-II studies using intraarterial and intrapleural having not only resources but also clinical collaboraadministration are now under way.
tors willing to test and develop the drugs for clinical
"L-NDDP is the first anti.tumor agent synthesized evaluation.
and developed entirely at M. D. Anderson," said
"One of my goals is to take my science from the
Perez-Soler. "As a result of our effort.s, we have been bench to the bedside," Khokhar said, "but without
able to make available a new anticancer agent to clinicians like Lopez-Berestein and Perez-Soler, I could
patient.s who have failed current therapies. We are never do that."
continued on page 2
proud we could do it within an academic hospital
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to ensure clinical utility, and would these modifications preserve anti.tumor activity while minimizing
toxic effects?
Perez-Soler, who had joined Lopez-Berestein's laboratory one year before to develop liposome technology for the delivery of chemotherapeutic agents, went
to the laboratory with the analogue Khokhar had
developed in 1982. "Dr. Perez-Soler did all of the
painstaking, difficult experimentation, testing the analogue with various formulations. Without his dedication, our progress would not have been possible,"
Khokhar said.

Freeze-fracture
electron micrograph of L-NDDP
in mouse lung.

Chance reading of engineering newsletter provides
clue to L-NDDP

Liposomes target specific organs
Iiposomes had two endearing qualities: They could,
theoretically, allow the infusion of an otherwise
uninfusible drug, and they tended to target organs
that are rich in phagocytes and that have fenestrated
capillaries, such as the liver, spleen, and bone marrow.
They could therefore be used to deliver drugs to
specific types of tumors. But liposomes also had a
quality that was not so endearing: they leaked or
dissolved before reaching their intended target.
Attempts at entrapping cisplatin in liposomes had
shown a mea er 7.4% efficien , but investi ators
attributed this more to cisplatin's lack oflipophilicity.
The quality that made cisplatin infusible-its affinity
for water rather than lipids-is the same quality that
made it unsuitable for liposomes. But with a lipophilic
analogue, Khokhar was confident that he and his
collaborators could improve on 7.4%, although he
well suspected that lipophilicity, in itself, would not
guarantee efficient encapsulation. Khokhar knew that
a lot of work testing various structural modifications
lay ahead. The major questions were, would such
modifications improve encapsulation efficiency enough

For a first attempt, Perez-Soler's results were striking: a 50% entrapment efficiency, about six times
better than that of cisplatin liposomes. Nevertheless,
to maximize encapsulation efficiency, they decided to
modify the structure of their current analogue. Their
research was helped along by Khokhar's chance reading of Chemical and Engineering News, in which he
noticed an advertisement for neodecanoic acid. The
advertisement gave him an idea that would ultimately
result in L-NDDP. "Neodecanoic acid is used as a
detergent in the oil industry. It has no anti.tumor
activity," Khokhar said, "but it interested me because
of the number of carbons it contains. In general, the
more carbons a molecule has, the more lipophilic it is."
Khokhar decided, therefore, to use neodecanoic
acid as a way to add more carbons to a specific part of
the analogue molecule. The result was L-NDDP, an
analogue that has a chain of 10 carbons attached to the
platinum atom. (L-ND DP also differs from cisplatin
in that it contains a molecule called diamminocydohexane, a modification that Khokhar had helped
discover in the early 1970s. Many of his analogues
developed since that time contain this modification,
because it confers non-cross-resistance with cisplatin.)
L-ND DP had an entrapment efficiency ofgreater than
95%. In addition, Perez-Soler found that it could be
easil re ared as a 1 o hilized owder that, u n
reconstitution on the day of intended use, would
produce a suspension ofliposomes containing NDDP.
When tested in five tumor models, it showed little
nephrotoxicity, better anti.tumor activity than cisplatin, and non-cross-resistance. It did, however, cause
myelosuppression.
These encouraging results encouraged Perez-Soler
to perform extensive toxicity studies in dogs, the
results of which were used to apply for FDA approval
to start clinical trials. An investigational new drug
exemption was approved in 1989, and a phase I study
continued on page 5
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Brief counseling could double quit rate

The physidan's role in smoking cessation
About 2 .5 percent ofAmerican smokers quit smoking each year. However, with more physician intervention, the quit rate could double to 5 percent, said Al
Kondo, Ph.D., M.P.H., instructor in cancer prevention
at The University of Texas M. D. Anderson Cancer
(..::Cnter. That increase may sound miniscule, Kondo
said, but it translates into thousands of additional exsmokers a year. ''We know that 434,000 Americans die
of smoking-related causes annually," he said. "Physid ans can do a lot to change this."
According to the National Center for Health Statistics, smokers visit a physician an average of 4.3
times a year, and 70 percent of all smokers see a
physician at least once a year. Thus, physicians have
the opportunity to deliver a regular message to many
smokers. Furthermore, Kondo said, patients pay more
attention to health-related messages from their doctors than they do messages from the media or from
their families. "What physicians say has so much
influence on patients," said Kondo, who provides
behavioral change counseling to patients and corporate clients through M. D. Anderson Cancer Center's

llieCheq™ program. "Just a few words of advice and
support can have a great deal of impact."
Kondo recognizes that the demands on a physician's
time are great, but the counseling techniques that he
recommends are simple and can be done quickly. "The
goal is not that all physicians should be bang-up counselors," Kondo said, "but simply that they should say
something to their patients who smoke." He suggests
that even specialists, such as thoracic surgeons, who do
not normally consider primary prevention efforts their
territory have a golden opportunity to influence patients
who have diseases caused by smoking.
The National Cancer Institute suggests four ways
(all beginning with the letter 'A') that smoking cessation counseling can be incorporated into physicians'
practices: Ask patients if they smoke, Advise smokers
to quit, ~ist patients in quitting, and Arrange for
follow-up.

Cancer Prevention

Al Kondo is an instructor in ·
cancer prevention in the
Department of Behavioral
Science

Helping the patient become ready to quit
The first two steps, asking whether patients smoke
and advising that smokers quit, only take a couple of
continued on page 4
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'-Some people feel fairly miserable
for a while, so you have to encourage
them to hang in there~

minutes, Kondo notes. He suggests a supportive, positive approach to advising, rather than trying to scare the
patient or inspire guilt. "Respect the individual," Kondo
said. "Smoking is a person's right. Ifyou push too hard,
you might alienate the patient." The message can be
tailored to the individual's health history, Kondo said.
For example, a physician might say, "Mary, your bronchitis could really be helped if you quit smoking."
It may take years for a person to become ready to
quit, Kondo said. At a "teachable moment," e.g., the
occurrence of a respiratory problem obviously asoociated with smoking, a patient might be more receptive
to messages about quitting. Many lung cancer patients
are able to give up the habit; in fact, in doing so, they
may feel they are contributing to their treatment, Kondo
said. In addition, surgeries are followed by a smoke-free
period; patients may be able to use the momentum of
this forced abstinence to give up tobacco permanently.
Choosing the appropriate quitting strategy
Once the patient has decided to quit, the physician's
role is to assist. The physician can help the patient decide
whether to cease nicotine use abruptly or to taper off
According to Kondo, quitting "cold turkey" is generally appropriate for individuals who do not smoke more
than a pack of cigarettes a day, do not have severe
withdrawal symptoms, and feel mentally ready for this
approach. Individuals who are heavier smokers, are
nicotine dependent (suffer excessive withdrawal symptoms), or don't think they can stop abruptly may prefer
nicotine fading (tapering off the number of cigarettes
smoked). Physicians can use the Fagerstrom Tolerance
Questionnaire to predict nicotine dependence. "The
question I use the most is 'When do you have your first
cigarette of the day?"' Kondo said. "The shorter the
interval between rising and the first cigarette, the more
likely the individual is nicotine dependent."
Nicotine-dependent individuals may benefit from
nicotine replacement therapy. The nicotine patch and
nicotine gum have been shown to increase quit rates by
reducing the physical impact of smoking cessation on
the patient while he or she makes the behavioral change.
Both the patch and the gum are designed to release a
steady flow ofnicotine into the bloodstream. Behavioral
counseling must accompany both therapies, Kondo
said. The patient should quit smoking before using the
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patch or gum.
Once a patient has decided to quit and knows which
approach to take, the next step is to set a quit date.
Kondo suggests putting the date in writing in a "contract" to encourage the patient to take it seriously. In
choosing the quit date, the physician and patient should
consider whether smoking is a more important part of
the patient's weekday routine or weekend routine,
Kondo said. For example, ifthe individual smokes more
on weekends, then quitting on Monday morning allows five nonsmoking days before the time of most
temptation.
Kondo recommends encouraging the patient to
change brands periodically before the quit date. The
rationale of this strategy is that it's easier to give up a
brand you find distasteful than to give up your favorite
brand. Kondo does not recommend switching to
chewing tobacco or snuff as an intermediate step. He
tried this strategy himself20 years ago when he stopped
smoking cigars and pipes. "The lungs are better off,
but chewing tobacco is terrible for the oral region," he
said. "Chewing tobacco can deliver the same amount
ofnicotine as a cigarette, and you have a new bad habit
to break."
Following up
After cigarette use is stopped, the smoker's circulatory system and lungs are cleared of carbon monoxide
and nicotine within two to three days, Kondo said.
According to a 1991 review by Belgian researchers S.
Beckers and Frederic Camu, normal ciliary function
returns in four to six days, sputum production decreases
in two to six weeks, and immune function improves in
six to eight weeks. It may take more than eight weeks
for pulmonary irritation to dear up. "Some people can
breathe better and have more energy right away,"
Kondo said. "However, some people feel fairly miserable for a while, so you have to encourage them to hang
in there."
Common symptoms of nicotine withdrawal are
irritability, insomnia, constipation, difficulty concentrating, lightheadedness, a tight feeling in the chest,
and cravings for tobacco. Except for irritability and
cravings, Kondo said, these conditions can be expected to last only about two weeks. Weight gain is
almost inevitable after smoking cessation, he said, and
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'-Just a few words of advice
and support can have a great
deal of impact~
•

•

•

can motivate some people to start smoking again. He
suggests telling patients who quit smoking to step up
their exercise routines and watch their diets. If weight
gain is a major concern, suggesting that the patient
join a group like Weight Watchers for maintenance
purposes may even be a good idea, he said.
Seventy percent ofpeople who quit smoking relapse
within three months, Kondo said. The physician can
help prevent relapse by following up with encouraging
messages. If the patient is being treated for a chronic
illness, office visits provide an opportunity for these
messages. "Unfortunately, visits just for smoking cessation counseling are not reimbursed by most insurance
companies," Kondo said, ''which is absurd, because so
many health problems are associated with smoking."
However, a phone call from the physician or from a
nurse or staff member takes less than five minutes, he
said. "I call on the quit date, two or three days later, and
again a few days later to provide reinforcement," Kondo
said. "Just the contact means a lot to the patient." He

Cisplatin Analogue
continued from page 2
ofintravenous L-ND DP was started immediately thereafter. The results indicated that the toxic effects of
intravenous L-NDDP in humans mirror those of the
animal studies: no dose-limiting nephrotoxic effects
were observed, but the bone marrow was suppressed.
The two phase I -II studies now being conducted at
M. D. Anderson will explore the potential pharmacologic advantage provided by liposomes when administered by intrapleural and intraarterial routes.
Although Khokhar and Perez-Soler are quite pleased
with the progress of the studies that have been done so
fur, L-NDDP is still years away from standard application. "The drug development process is very long. It
can take 15 years for a drug to go through the necessary studies and regulatory approvals," said Khokhar,
who hesitates to estimate when L-NDDP or a drug
like it will be available. ''We don't like to make predictions. Doing so sometimes gives false hopes. One
reason for our success is that we treat these issues very
conservatively. Although our results with L-NDDP

•

•

•

•

suggests words of support: "How are you doing with
your smoking, Joe? How are your withdrawal symptoms? Are you breathing better? Is your illness better
since you quit?" Another option is sending a postcard.
"The amount of effort put into counseling a patient
depends on several factors, like how committed the
patient is and whether the patient has a smoking-related
condition," Kondo said. "Realistically, smoking cessation counseling is just one of many aspects of the
physician's practice." However, with a small investment
of time, Kondo believes, physicians can play a pivotal
role in encouraging patients to give up tobacco permanently.
-SUNITA PATTERSON

Physicians who desire additional information may write
Dr. Al Kondo, Department of Behavioral Science, Box
243, The University of Texas M. D. Anderson Cancer
Center, 1515 Holcombe Blvd., Houston, Texas 77030,
or call (713) 792-0919.

have been promising, we'll have to wait and see."
Perez-Soler added, ''We know that L-NDDP, from
a pharmaceutical point of view, is probably not the
best compound within the family of analogues we are
studying, because it's a mixture ofisomers and tends to
be unstable within the liposomes; L-NDDP gives us,
however, the opportunity of testing the therapeutic
concept of a lipophilic platinum compound delivered
in a drug carrier, which is a novel idea. Should the
current and future phase II studies show that this
approach has a real therapeutic value, we may have to
substitute one of its isomers or a closely related analogue that has better stability characteristics."
-KEVIN FLYNN

Physicians who desire additional information may write
Dr. Abdul Khokhar, Department of Clinical Investigation,
Box 52, or Dr. Roman Perez-Soler, Department of
Thoracic/Head and Neck Medical Oncology, Box 80,
The University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Blvd., Houston, Texas 77030, or call
(713) 792-2837 (Khokhar) or 792-6363 (Perez-Soler).
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Understanding Risk
continued from page 8

II
The proportion of cancer deaths has indeed
risen, but some of the increase is due to
reduction in death rates from other diseases
and a longer life expectancy

Shallenberger agreed that the public perceives
the overall risk of cancer to be greater now than it
once was, with some justification. He cites discoveries of previously unknown risk factors and carcinogens, which are often widely and sensationally
covered in the popular media, as a major contributor to this perception. It is true that the proportion
of cancer deaths in this country has increased in the
last 60 years, but the threat of death from many
non-cancer-related diseases has been reduced or eliminated, Shallenberger said, so that life expectancy has
increased considerably in this century. "Cancer is largely
a disease of older people," said Shallenberger. "There
are more and more relatively healthy older people
available to develop cancer."
Shallenberger also said that the methods of collecting data about cancer incidence and mortality,
although still far from perfect, have improved significantly, making current data more reliable. However, this creates the appearance that the incidence
of cancer, or the number of new cases in a given
population during a specified period, has increased
more than it actually has. In describing the battle to
keep accurate and reliable statistics on cancer risk,
Shallenberger also cited the improvements in treatment of several kinds of cancer that have dramatically reduced cancer fatalities. Because cancer
mortality is no longer as accurate an indicator of
incidence as it once was, it has become necessary to
monitor trends in cancer incidence rather than canrm
keeping is a much more difficult task.

Probabilities are a better indication of risk
than are incidence rates

The probabilities of developing cancer, which are
shown on life tables, are sensitive to changes over
time in incidence and mortality. Life tables allow us
to construct estimates of the changing risk of developing cancer by age, sex, and race. They can be
constructed for all cancer sites combined or for
individual sites. The development of life tables requires that living individuals who do and do not
develop cancer be counted. Because individuals are
dismissed when they die of other causes, the life
table methodology is sensitive to the reduction in
noncancer mortality that changes in incidence rates
do not express directly. For example, the lifetime
probability of developing prostate cancer is higher
for white males than for black males, even though
the age-specific incidence rates are higher for blacks
than for whites in almost every age group. This
apparent contradiction occurs because mortality due
to other causes is higher for blacks.

II

Life Table Sources

More sensitive and widely used screening
methods detect more cancers, including
premalignant lesions

To obtain more information on life tables,
contact the Surveillance Program, Division of Cancer Prevention and Control,
National Cancer Institute, Executive Plaza
North, Room 3431, Bethesda, MD
20892-9903. Phone: (301) 496-8510.

Another factor that makes cancer risk estimation
difficult is the effect of screening programs. Today's
more widespread screening programs are causing an
increase in reported incidence. Shallenberger cau-
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tioned, however, that most of this reported increase
should be attributed to greater numbers of people
being screened; it is inappropriate to conclude from
this increase that there has been an increase in
prevalence of the agents that cause these tumors.
Each of these factors in a different way creates the
incorrect perception that the risk of cancer is increasing rapidly. "It is not surprising," Shallenberger
said, "that the perception of the relative importance
of cancer as a cause of death, along with the steady
stream of reports in the newspapers, television, and
other media about cancer risks, should lead people
to believe that our success in discovering avoidable
causes of cancer and improving treatment of cancer
is outweighed by the spread ofnew hazards." It's no
wonder, said Shallenberger, that "there's a popular
perception that we're not making progress."
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"The much-repeated one in eight
risk of breast cancer applies only to
white female infants"
•

•

•

Cumulative does not equal individual risk
"The key," continued Shallenberger, "is that the
risk estimates presented in life tables are cumulative
risks over time. The patient's current age must be
taken into account when determining his risk, since
a person who has lived to, say, age 65 has escaped
other causes of death. The much-repeated one in
eight risk of breast cancer applies only to white
female infants-and only if current incidence and
mortality patterns remain unchanged during their
lifetime. Yet it's being applied out of context to
women of all ages . Actually, a 60-year-old white
woman has a 1 in 10 chance of eventually developing breast cancer, and the chance for a SO-year-old
black woman is less than 1 in 12. Some experts,
therefore, are now suggesting that risk be framed as
the chance of developing cancer in the near futuresay, within the next year. When this risk figure is
calculated, it is generally much, much lower: about
one in 3,700 for a woman in her 30s."
Another misconception that arises from the reporting of these statistics is when the incidence
appears to increase. For example, in the early 1980s,
before the dramatic increase in mammography utilization, the lifetime risk of a woman developing
breast cancer was one in ten. In the space of only a
few years, this risk was reported to have increased to
one in nine and then to one in eight. This created
the perception that millions more young and middleaged women had been affected over a short period
oftime. "That's painfully wrong," said Shallenberger.
What really happened was that, as already cited, the
reported incidence had increased because of more
widespread screening; moreover, the method had
changed to account for a longer life expectancy.
Guidelines for physicians
The most important thing for a physician to do,
says Shallenberger, is to listen when the patient who
has no special risk factors expresses an unreasonable
amount of anxiety about or interest in cancer risk.
Remember that the patient may find it difficult to
understand the statistics she or he finds in the media.
Since most patients are thinking only of the near
future, the next few years, it's very important that
the physician emphasize what the risk is for that

•

•

•
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patient now. The physician should keep a set of upto-date risk tables available and use them to show
patients their estimated risk based on their age, sex,
and race, thus reducing anxiety. The physician should
remind fearful patients that these estimates are reliable because they are based on the past experiences
of large samples of the population. However, because they refer to averages, they relate to a patient
by his or her membership in a group and cannot be
used to precisely determine his or her risk. Although
these tables should not be applied to people who fall
into certain high-risk categories, in most cases the
physician will be able to show patients that their risk
is much less than they had feared.
Moreover, said Shallenberger, declines in incidence are almost always real. The risk of developing gastric cancer, for example, has dropped
dramatically in this country during this century. He
does acknowledge, however, that the lifetime risk
estimates of developing any kind of cancer were
somewhat higher in 1988 than they were in 1980
(about 8% higher for adult white males). Experts
suspect that only about one third of this increase is
actually due to increased cancer incidence. Another
third is attributed to declines in death rates from
other diseases, and the final third is thought to be a
result of variations in the statistical methodology.
Shallenberger chooses to emphasize the positive:
he expects that the cumulative effects of better
screening and increased detection and treatment of
premalignant lesions will eventually reverse the true
incidence figures. Furthermore, he urges physicians
to remind their fearful patients that much progress
has been made in diagnosing and managing cancer
and that behavioral changes such as quitting smoking have a profound effect on cancer risk.
-KAT HRYN L. HALE
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M. D. Anderson's Shallenberger
gives three simple guidelines

Physicians can help allay fear by helping
patients understand cancer risk
Cancer Awareness

Rick Shallenberger is an
assistant epidemiologist in
the Department of
Patient Studies

Just about any primary care physician will tell
you: more and more patients are aware of cancer
risks and increasingly uneasy about their own chances
of developing cancer. Patients are bombarded with
information about risk factors for different cancers,
some o 1t contra ctory, most o 1t mys enous.
They turn to their primary care physicians for advice
and reassurance. They want to know, how can I
keep from becoming one of these statistics? Young
healthy women anxious about breast cancer ask for
prophylactic mastectomies. They have heard that
one in eight women will get breast cancer, and they
do not want to be the one. They are not alone. Men
and women in many different age, ethnic, socioeconomic, and occupational groups, similarly fearful
about developing cancer, are looking to their primary care physicians for ways to prevent the disease.

Although some of these people, b cau of th ir
family history or their own medical hi tory trul fall
into high-risk categories, many oth r do not. Ar
these fears justified, or is there an pid mic f
cancerphobia?
c
en erger, . . ., an ep1 ermo ogi
in the Department of Patient Studie at M. D. Anderson Cancer Center, belie es that primary care
physicians can allay their patients fears-real or
otherwise-by understanding the methods used to
estimate risk. Armed with this kno ledge ph icians can help their patients interpret the statistics
and apply them to their own situations. According
to Shallenberger, physicians should keep three things
in mind when talking to patients about risk. Doing
so, he believes, can create a more rational basis for
health care and behavioral decision making.
continued on page 6

